Vanda Pinto, PhD, science writer —

Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

FDA Names Anavex2-73, Potential Fragile X Therapy, an Orphan Drug

Anavex2-73 (blarcamesine), an experimental small molecule being developed by Anavex Life Sciences, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) as a potential treatment of fragile X syndrome. This designation is given to investigational treatments for people with rare diseases, defined…

Ovid Stops Development and Testing of OV101 for Fragile X

Ovid Therapeutics announced it is discontinuing work to further develop or test OV101 (gaboxadol) as a potential treatment of fragile X syndrome. Although OV101 was found to be safe and well tolerated in multiple clinical trials, its overall efficacy in these studies fell short, Ovid Therapeutics said in a…